Based on recent data, Nasus Pharma Ltd. (NSRX) shows an Average True Range (ATR) of 0.69 and an Enterprise Value of N/A. Its average trading volume over the past 3 months is 172.98K, indicating liquidity. These fundamental metrics provide insight into NSRX's underlying financial health and market activity.
| ATR | 0.69 |
| Enterprise Value | - |
| Avg Vol (3 Months) | 172.98K |
| Avg Vol (10 Days) | 27.99K |
Nasus Pharma Ltd. (NSRX) technical indicators as of April 20, 2026: the SMA 20 is -7.9%, SMA 50 at -21.08%, and SMA 200 at -29.02%. The RSI 14 value is 41.5, suggesting its current momentum. These technical analysis signals help assess NSRX's price trends and potential future movements.
| SMA 20 | -7.9% |
| SMA 50 | -21.08% |
| SMA 200 | -29.02% |
| RSI 14 | 41.5 |
Nasus Pharma Ltd. (NSRX) stock performance overview as of April 20, 2026: The 52-week high is N/A (currently -48.95% below), and the 52-week low is N/A (currently 4.08% above). Over the past year, NSRX's performance is N/A, compared to the S&P 500's 25.03% change.
| 52-Week High | N/A |
| 52-Week High Chg | -48.95% |
| 52-Week Low | N/A |
| 52-Week Low Chg | +4.08% |
| S&P 500 52-Week Chg | 25.03% |
According to current financial data, NSRX stock's P/E (TTM) ratio is -13.25, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.22. Key valuation ratios for NSRX, including P/S (N/A), P/B (N/A), and P/FCF (N/A), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
| Valuation | NSRX | Sector Median | Industry Avg | S&P 500 |
|---|---|---|---|---|
| P/E (TTM) | -13.25 | -1.22 | -5.12 | 32.59 |
| P/S (TTM) | N/A | 3.69 | 464.32 | 5.98 |
| P/B (TTM) | N/A | 0.21 | 0.65 | 4.99 |
| P/FCF (TTM) | N/A | -2.63 | -497.8 | 34.68 |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep